[2-(Dimethylamino)-2-oxoethyl] 1-[3-(2-methylsulfonylphenothiazin-10-yl)propyl]piperidine-4-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 英文名称: [2-(Dimethylamino)-2-oxoethyl] 1-[3-(2-methylsulfonylphenothiazin-10-yl)propyl]piperidine-4-carboxylate
• 英文别名: [2-(dimethylamino)-2-oxoethyl] 1-[3-(2-methylsulfonylphenothiazin-10-yl)propyl]piperidine-4-carboxylate
• 化学式: C₂₆H₃₃N₃O₅S₂
• 分子量: 531.7
• InChiKey: GHXVHYUSXNOTMJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  36
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  121
• 氢给体数：
  0
• 氢受体数：
  8

文献信息

• Methods for treating GI tract disorders
  申请人：Neurogastrx, Inc.

  公开号：US11147820B2

  公开（公告）日：2021-10-19

  Provided herein are methods, compositions, and kits for the treatment of an enteric nervous system disorder. Such methods may comprise administering to a subject an effective amount of a phenothiazine compound, a peripherally restricted dopamine decarboxylase inhibitor, and/or a peripherally restricted dopamine D2 receptor antagonist that does not substantially inhibit hERG channels.

  本文提供了用于治疗肠神经系统疾病的方法、组合物和试剂盒。这些方法可包括向受试者施用有效量的吩噻嗪化合物、外周限制性多巴胺脱羧酶抑制剂和/或外周限制性多巴胺 D2 受体拮抗剂，它们不会对 hERG 通道产生实质性抑制作用。
• METHODS FOR TREATING GI TRACT DISORDERS
  申请人：Neurogastrx, Inc.

  公开号：EP2934540A1

  公开（公告）日：2015-10-28
• Methods for Treating GI Tract Disorders
  申请人：Neurogastrx, Inc.

  公开号：US20150087638A1

  公开（公告）日：2015-03-26

  Provided herein are methods, compositions, and kits for the treatment of an enteric nervous system disorder. Such methods may comprise administering to a subject an effective amount of a phenothiazine compound, a peripherally restricted dopamine decarboxylase inhibitor, and/or a peripherally restricted dopamine D2 receptor antagonist that does not substantially inhibit hERG channels.
• PRODRUGS OF METOPIMAZINE
  申请人：Neurogastrx, Inc.

  公开号：US20170143734A1

  公开（公告）日：2017-05-25

  Provided herein are methods, compounds, compositions, and kits for the treatment of an enteric nervous system disorder. Such methods may comprise administering to a subject an effective amount of a phenothiazine compound, a peripherally restricted dopamine decarboxylase inhibitor, and/or a peripherally restricted dopamine D2 receptor antagonist that does not substantially inhibit hERG channels.
• US9132134B2
  申请人：——

  公开号：US9132134B2

  公开（公告）日：2015-09-15